|1.||Ohio State University Phase II Research Consortium Study: 1 article (01/2002)|
|2.||Vandre, Dale D: 1 article (01/2002)|
|3.||Moore, Timothy: 1 article (01/2002)|
|4.||Galloway, Sharon: 1 article (01/2002)|
|5.||Fine, Howard: 1 article (01/2002)|
|6.||Yung, W K Alfred: 1 article (01/2002)|
|7.||Kunschner, Lara J: 1 article (01/2002)|
|8.||Kraut, Eric H: 1 article (01/2002)|
|9.||Thomas, Jason P: 1 article (01/2002)|
|10.||Kyritsis, Athanassios P: 1 article (01/2002)|
|1.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2002 - "Due to the preclinical activity of CI-980 and its similar mechanism of action to drugs effective in small cell lung cancer, a phase II trial in extensive small cell lung cancer was initiated by The Ohio State University Phase II Research Consortium. "
01/01/2002 - "We conclude that despite antitumor activity demonstrated in preclinical studies, CI-980 does not have biological activity in previously untreated small cell lung cancer at this dose and infusion protocol."
01/01/2002 - "A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study."
01/01/2002 - "The purpose of this phase I/II trial was to determine the maximal tolerated dose of CI-980, and determine efficacy against malignant glioma. "
01/01/2002 - "These results fail to demonstrate the significant activity of CI-980 against recurrent glioma."
01/01/2002 - "CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980."
11/01/1999 - "Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study."
01/01/1997 - "A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors."
01/01/2002 - "In preclinical tumor models, CI-980 showed a broad spectrum of activity, including in multi-drug resistant tumor cell lines, with activity at least equal to that of vincristine. "
11/01/1999 - "To establish the maximum tolerated dosage (MTD), the dose-limiting toxicities (DLTs), and pharmacokinetic parameters of CI-980, a novel tubulin binder, in children with solid tumors refractory to standard therapy. "
06/09/1995 - "CI-980 has shown equivalent or superior anticancer activity in vitro compared to vincristine and retains full activity against vincristine resistant tumors in vitro. "
|4.||Melanoma (Melanoma, Malignant)
01/01/2001 - "CI-980 administered at this dose and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further investigation."
01/01/2001 - "Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. "
05/01/2000 - "CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer."
05/01/2000 - "CI-980 in advanced melanoma and hormone refractory prostate cancer."
|5.||Colorectal Neoplasms (Colorectal Cancer)
|1.||Drug Therapy (Chemotherapy)